Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
AstraZeneca Climbs, Glencore Rises, Argenx Surges | Stock Movers
Posted
August 17, 2026
Views
238
Likes
2
Engagement
0.84%
August 17, 2026
238
2
0.84%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
3:34Now PlayingToday's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- AstraZeneca shares rise after the pharmaceutical giant said it is stopping a clinical trial of the experimental drug volrustomig after it didn’t look set to help fight lung cancer better than existing therapies.
- Glencore shares rise after Export-Import Bank of Korea announced it will lend $1 billion to the commodities giant in exchange for copper supply to South Korean companies, as the country seeks to secure raw materials needed for the artificial intelligence boom.
- Argenx jumps as much as 10%, the most in more than a year, after the company announced positive late-stage trial results for its experimental myositis treatment.
See omnystudio.com/listener () for privacy information.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Check out more episodes of Stock Movers
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
#Stocks #Markets #Finance #Investing #Podcast #Bloomberg
AstraZeneca Climbs, Glencore Rises, Argenx Surges
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
